Guggenheim Maintains Buy on Immunovant, Raises Price Target to $32
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Yatin Suneja maintains a Buy rating on Immunovant (NASDAQ:IMVT) and raises the price target from $30 to $32.
May 23, 2023 | 2:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim analyst Yatin Suneja maintains a Buy rating on Immunovant and raises the price target from $30 to $32.
The news of Guggenheim maintaining a Buy rating and raising the price target for Immunovant is positive for the company's stock. This indicates that the analyst has a favorable view of the company's prospects and expects the stock price to rise in the short term. As a result, this news is likely to have a positive impact on IMVT's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100